Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid experienced patients. 

Pharmaceutical

Bridge Therapeutics

David Bergstrom

Greg Sullivan

Tim Peara

Alton S. Kelley

Bridge Therapeutics' Leadership Team includes Greg Sullivan and 3 others.

Leadership Team

About

Team members